Evidence Level:Sensitive: C1 - Off-label
(Approved for Melanoma)
New
Excerpt:ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Excerpt:...BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Excerpt:...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
More C2 evidence
![](/assets/chevron-circle-down-solid.svg)
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Excerpt:...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Less C2 evidence
![](/assets/chevron-circle-up-solid.svg)
Evidence Level:Sensitive: C3 – Early Trials
New
Title:
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience
Excerpt:Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.
Evidence Level:Sensitive: C4 – Case Studies
New
Title:
Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
Excerpt:"The patient's PTC underwent a comprehensive genomic profile and was identified as harboring BRAF V600E. She started with 960 mg of vemurafenib twice daily...Two months later, repeat PET imaging demonstrated a dramatic reduction in both 18F-fluorodeoxyglucose avidity and mass size...
Evidence Level:Sensitive: D – Preclinical
Title:
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
Excerpt:Drug sensitivity assays of PTC organoid cultures demonstrated the intra- and inter-patient specific drug responses. BRAFV600E inhibitors, vemurafenib and dabrafenib monotherapy was mildly effective in treating BRAFV600E-mutant PTC organoids.
DOI:10.1186/s12967-022-03848-z